Eli Lilly has experienced significant growth, reaching a market capitalization over $1 trillion. The company aims to maintain its leadershi...

Sandoz plans to more than double annual net sales by 2035, with biosimilars leading growth. The company will expand its biosimilar portfoli...

Aurobindo Pharma shares rose sharply after its subsidiary Lannett Company launched the generic equivalent of Advair Diskus in the US. The i...

India sees a significant rise in overweight and obese populations recently. Rural areas show a particularly sharp increase in these health ...

Sun Pharma's June quarter results met analyst expectations, signaling future growth. The company is expanding its specialty and innovative ...

Indian drugmakers have launched affordable generic versions of popular diabetes and weight-loss drugs. This move significantly reduces trea...

Eli Lilly's diabetes drug Mounjaro will be added to China's state health insurance from January 1, making it more accessible to the country...

Biocon has partnered with Brazil-based Biomm SA for the commercialization of its diabetes drug, Semaglutide (gOzempic). Biocon will develop...

The Biocon subsidiary will chart a path that ensures high volumes and low costs, unlike competitors. The company plans to create an ecosyst...

Abbott will also look at partnering with e-pharmacies, diagnostic chains and physicians to provide patients with discounts.

US pharma major Eli Lilly plans to launch a new medication by the end of this year to enhance its diabetes treatment portfolio in India.

The Delhi high court wrestled with defining `junk food', following the PIL by the Delhi-based Uday Foundation to ban such food in schools.

Novo Nordisk launched it's combination diabetic drug Ryzodeg, priced at Rs 1,595 for 300 units, for people with type II diabetes in India.

The report said factors that would contribute to the growth of wound care market include rising awareness regarding new and advanced produc...

Zydus Hospitals & Healthcare Research recently started its first hospital operations at Anand, better known as Amul's hometown.

Lupin recently enhanced its presence in Japan with the acquisition of I'rom Pharmaceuticals in November this year for an undisclosed amount.

Healthcare major, Zydus Cadila has filed IND (Investigational New Drug) application for anti-diabetic and anti-obesity drug with Drugs Cont...